PURPOSE: To identify prognostic factors, define evolving patterns of care, and the effect of targeted therapies in a larger contemporary cohort of renal cell carcinoma (RCC) patients with new brain metastases (BM). METHODS AND MATERIALS: A multi-institutional retrospective institutional review board-approved database of 711 RCC patients with new BM diagnosed from January 1, 2006, to December 31, 2015, was created. Clinical parameters and treatment were correlated with median survival and time from primary diagnosis to BM. Multivariable analyses were performed. RESULTS: The median survival for the prior/present cohorts was 9.6/12 months, respectively (P < .01). Four prognostic factors (Karnofsky performance status, extracranial metastases, number of BM, and hemoglobin b) were significant for survival after the diagnosis of BM. Of the 6 drug types studied, only cytokine use after BM was associated with improved survival. The use of whole-brain radiation therapy declined from 50% to 22%, and the use of stereotactic radiosurgery alone increased from 46% to 58%. Nonneurologic causes of death were twice as common as neurologic causes. CONCLUSIONS: Additional prognostic factors refine prognostication in this larger contemporary cohort. Patterns of care have changed, and survival of RCC patients with BM has improved over time. The reasons for this improvement in survival remain unknown but may relate to more aggressive use of local brain metastasis therapy and a wider array of systemic treatment options for those patients with progressive extracranial tumor.
PURPOSE: To identify prognostic factors, define evolving patterns of care, and the effect of targeted therapies in a larger contemporary cohort of renal cell carcinoma (RCC) patients with new brain metastases (BM). METHODS AND MATERIALS: A multi-institutional retrospective institutional review board-approved database of 711 RCCpatients with new BM diagnosed from January 1, 2006, to December 31, 2015, was created. Clinical parameters and treatment were correlated with median survival and time from primary diagnosis to BM. Multivariable analyses were performed. RESULTS: The median survival for the prior/present cohorts was 9.6/12 months, respectively (P < .01). Four prognostic factors (Karnofsky performance status, extracranial metastases, number of BM, and hemoglobin b) were significant for survival after the diagnosis of BM. Of the 6 drug types studied, only cytokine use after BM was associated with improved survival. The use of whole-brain radiation therapy declined from 50% to 22%, and the use of stereotactic radiosurgery alone increased from 46% to 58%. Nonneurologic causes of death were twice as common as neurologic causes. CONCLUSIONS: Additional prognostic factors refine prognostication in this larger contemporary cohort. Patterns of care have changed, and survival of RCCpatients with BM has improved over time. The reasons for this improvement in survival remain unknown but may relate to more aggressive use of local brain metastasis therapy and a wider array of systemic treatment options for those patients with progressive extracranial tumor.
Authors: James E Bates; Paul Youn; Carl R Peterson; Kenneth Y Usuki; Kevin A Walter; Paul Okunieff; Michael T Milano Journal: Am J Clin Oncol Date: 2017-10 Impact factor: 2.339
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Paul W Sperduto; Penny Fang; Jing Li; William Breen; Paul D Brown; Daniel Cagney; Ayal Aizer; James Yu; Veronica Chiang; Supriya Jain; Laurie E Gaspar; Sten Myrehaug; Arjun Sahgal; Steve Braunstein; Penny Sneed; Brent Cameron; Albert Attia; Jason Molitoris; Cheng-Chia Wu; Tony J C Wang; Natalie Lockney; Kathryn Beal; Jessica Parkhurst; John M Buatti; Ryan Shanley; Emil Lou; Daniel D Tandberg; John P Kirkpatrick; Diana Shi; Helen A Shih; Michael Chuong; Hirotake Saito; Hidefumi Aoyama; Laura Masucci; David Roberge; Minesh P Mehta Journal: Transl Res Date: 2019-02-27 Impact factor: 7.012
Authors: Paul W Sperduto; Brian J Deegan; Jing Li; Krishan R Jethwa; Paul D Brown; Natalie Lockney; Kathryn Beal; Nitesh G Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Amir Zahra; John M Buatti; James B Yu; Veronica Chiang; Jason K Molitoris; Laura Masucci; David Roberge; Diana D Shi; Helen A Shih; Adam Olson; John P Kirkpatrick; Steve Braunstein; Penny Sneed; Minesh P Mehta Journal: Neuro Oncol Date: 2018-11-12 Impact factor: 12.300
Authors: U Harmenberg; M Lindskog; G Sinclair; M Stenman; H Benmakhlouf; P Wersäll; P Johnstone; M A Hatiboglu; J Mayer-da-Silva Journal: Acta Neurochir (Wien) Date: 2020-09-09 Impact factor: 2.216
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: J Clin Oncol Date: 2020-09-15 Impact factor: 44.544
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Brahma D Natarajan; Christel N Rushing; Michael A Cummings; Jessica Ms Jutzy; Kingshuk R Choudhury; Michael J Moravan; Peter E Fecci; Justus Adamson; Steven J Chmura; Michael T Milano; John P Kirkpatrick; Joseph K Salama Journal: J Radiosurg SBRT Date: 2019
Authors: Sebastian Rubino; Daniel E Oliver; Nam D Tran; Michael A Vogelbaum; Peter A Forsyth; Hsiang-Hsuan Michael Yu; Kamran Ahmed; Arnold B Etame Journal: Front Oncol Date: 2022-03-02 Impact factor: 6.244
Authors: Martha Nowosielski; Georg Goebel; Sarah Iglseder; Ruth Steiger; Lukas Ritter; Daniel Stampfl; Johanna Heugenhauser; Johannes Kerschbaumer; Elke R Gizewski; Christian F Freyschlag; Guenther Stockhammer; Christoph Scherfler Journal: Clin Exp Metastasis Date: 2022-04-08 Impact factor: 5.150